التفاصيل البيبلوغرافية
| العنوان: |
SEOM clinical guideline for the management of malignant melanoma (2017) |
| المؤلفون: |
Berrocal, A., Arance, A., Castellón, V. E., Cruz Merino, Luis de la, Espinosa, E., Cao, M. G., Larriba, J. L. G., Marquez-Rodas, I., Soria, A., Algarra, S. M. |
| المساهمون: |
Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica. |
| بيانات النشر: |
Springer Int Publ Ag |
| سنة النشر: |
2024 |
| المجموعة: |
idUS - Deposito de Investigación Universidad de Sevilla |
| مصطلحات موضوعية: |
Melanoma, Metastatic, Adjuvant, Immunotherapy, B-RAF |
| الوصف: |
All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic mel anoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
Clinical and Translational Oncology, 20 (1), 69-74.; https://link.springer.com/article/10.1007/s12094-017-1768-1Test; https://idus.us.es/handle//11441/156158Test |
| الإتاحة: |
https://idus.us.es/handle//11441/156158Test |
| حقوق: |
Atribución 4.0 Internacional ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.24A62382 |
| قاعدة البيانات: |
BASE |
